



## ADULT MEDICATION GUIDELINE

# SPIRAMYCIN

<b>Scope (Staff):</b>	All WNHS Staff
<b>Scope (Area):</b>	Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

### Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and  
Breastfeeding](#)

### Restrictions

[Formulary: Highly Restricted](#)

[SAS Category A](#) (item requires approval by TGA)

### Medication Class

Macrolide

### Presentation

**Capsule:** 1.5 million units

### Storage

Store at room temperature, below 25°C

### Dose

#### Toxoplasmosis in Pregnancy

**Oral:**

American Academy of Pediatrics (AAP) dosing:

3 million units (1g), three times a day

French Multidisciplinary Working Group dosing:

3 million units (1g), three times a day

## Administration

### Oral:

Take on an empty stomach, at least half an hour before food or two hours after food.

## Monitoring

Ultrasound to detect abnormalities and amniocentesis for polymerase chain reaction (PCR) and / or culture at 18 - 20 weeks gestation or if  $\geq 4$  weeks after maternal infection

## Pregnancy

**1<sup>st</sup> Trimester:** Considered safe to use

**2<sup>nd</sup> Trimester:** Considered safe to use

**3<sup>rd</sup> Trimester:** Considered safe to use

## Breastfeeding

Considered safe to use

## Comments

## Related Policies, Procedures & Guidelines

### **HDWA Mandatory Policies:**

[Antimicrobial Stewardship](#)

### **WNHS Clinical Practice Guidelines:**

### **WNHS Pharmaceutical and Medicines Management Guidelines:**

## References

Maldonado Y.A., Read J.S. Committee on Infectious Diseases Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States. *Pediatrics*. 2017;139:2

Peyron F, et al; Maternal and Congenital Toxoplasmosis: Diagnosis and Treatment Recommendations of a French Multidisciplinary Working Group. *Pathogens*. 2019 Feb 18;8(1). pii: E24. doi: 10.3390/pathogens8010024.









[CDC Toxoplasmosis resources for Health Professionals](#)

Padberg S. Anti-infective agents. In: Schaefer C, Peters P, Miller R, editors. Drugs in pregnancy and lactation [Internet]. Amsterdam: Elsevier. 3rd ed., 2015 [cited 2017 Dec 12]. p. 115-76. Available from: <https://www-clinicalkey-com-au.kelibresources.health.wa.gov.au/#!/content/book/3-s2.0-B978012408078200007X>.

APILAM: association for promotion and cultural and scientific research of breastfeeding. Spiramycin. E-lactancia [Internet]. 2022 [cited 2022 Jan 19]. Available from: <http://www.e-lactancia.org/breastfeeding/spiramycin/product>

Truven Health Analytics. Spiramycin. In: Micromedex [Internet]. Greenwood Village (CO): Truven Health Analytics; 2022 [cited 2022 Jan 19]. Available from: <http://www.micromedexsolutions.com>

South Australian Maternal & Neonatal Community of Practice. Toxoplasmosis in pregnancy. South Australian Perinatal Practice Guidelines [Internet]. 2016 [updated 2015 Jun 24; cited 2017 Sept 20].

Keywords	Spiramycin, macrolide, toxoplasmosis				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	4.0				
Date First Issued:	31/03/2014	Last Reviewed:	19/01/2022	Review Date:	Jan2025
Endorsed by:	Medicines and Therapeutics Committee			Date:	01/03/2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input checked="" type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
<b>Printed or personally saved electronic copies of this document are considered uncontrolled.          Access the current version from WNHS HealthPoint.</b>					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.